KCNJ8 and migraine disorder: Basic mathematical modeling of pharmacokinetics and receptor potencies showed that the dose of glibenclamide used in clinical studies had receptor occupancy of 26% at the migraine relevant KATP channel subtype Kir6.1/SUR2B (83).